Frontlight ResearchEarly access
CompletedEarly phase 1
Methylphenidate and Response to Alcohol Cues Pilot Study
Key facts
- Who runs it
- University of Florida
- Where
- Gainesville, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Early phase 1
- People taking part
- 31 people enrolled
- Started
- 20 Mar 2024
- Ended
- 1 Jul 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Methylphenidate Pill
- Record updated
- 10 February 2026
Who can take part
- Age
- 18 years to 25 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Adults ages 18-25 years
- Meets DSM-5 criteria for AUD
- Meets DSM-5 criteria for ADHD
- Fluent in English
- Normal or corrected to normal vision
Who cannot take part
- Participant routinely uses psychoactive drugs or medications except for non-dependent marijuana or nicotine use (due to common use of these substances in individuals with AUD)
- Meets DSM-5 criteria for bipolar disorder, psychotic disorders, neurological disorders, or substance use disorders other than AUD
- Self-reported history of high blood pressure over 140/90 or consistent readings of 140/90 or above upon arrival for a session
- History of seizure disorder
- Liver disease
- Participant has contraindications for taking methylphenidate
- Participant has contraindications for being in an MRI machine
- Participant is currently pregnant or trying to become pregnant
Where in United States
- University of FloridaGainesville, United States
About the trial
What the trial wants to find out
The purpose of this study is to determine whether changes in attention levels related to taking a single dose of a medication called methylphenidate, also known as Ritalin, affects responses to alcohol cues. The study will observe the effects of methylphenidate or a placebo on attentional bias and craving responses to alcohol cues through fMRI, EEG, and behavioral testing. Participants will be involved in one remote and two in-person sessions.
The 2 groups in the trial
- crossover 1: methylphenidate, placeboOther group
methylphenidate (single dose, oral, 20 mg, immediate release) followed by placebo (single dose, oral)
Treatment: Methylphenidate Pill
- crossover 2: placebo, methylphenidateOther group
placebo (single dose, oral) followed by methylphenidate (single dose, oral, 20 mg, immediate release)
Treatment: Methylphenidate Pill
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Methylphenidate and Response to Alcohol Cues (MARA) Pilot Study
- Record updated
- 10 February 2026